0.19 | 1.19%
| Price and Volume | |
|---|---|
| Recent Price | 16.14 |
| 52 Week High | 20.00 |
| 52 Week Low | 13.48 |
| Avg. Daily Vol. (Mil) | 1.24 |
| Beta (3 year) | 0.70 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,102.09 |
| Shares Out (Mil) | 130.24 |
| Float (Mil) | 82.67 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.20 |
| Current Ratio | 3.80 |
| LT Debt/ Equity | 0.52 |
| Total Debt / Equity | 0.52 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.39 |
| Price/Book | 2.46 |
| Price/Cash Flow | -105.00 |
| Per Share Data | |
| Earnings | -0.99 |
| Sales | 2.99 |
| Book Value | 6.56 |
| Cash Flow | -0.15 |
| Business Summary | |
|---|---|
| Alkermes, Inc. is a biotechnology company committed to developing innovative medicines to improve patients' lives. | |
| General Information | |
| Treasury Building
Lower Grand Canal Street Dublin, 2 |
|
| www.alkermes.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1200 | |
| CEO: Richard F. Pops | |
| Short Interest | |
| Current Month (Mil) | 6.92 |
| Previous Month (Mil) | 6.95 |
| Short Interest Ratio (Days) | 7.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -7.90 |
| Return on Investments | -8.80 |
| Profitability | |
| Gross Margin | 73.10 |
| EBIT Margin | -22.10 |
| Profit Margin | -29.10 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet